
Loading, please wait...

Loading, please wait...
"Wherever the art of Medicine is loved, there is also a love of Humanity."
Hippocrates

Periventricular nodular heterotopia (PVNH) represents a complex malformation of cortical development. In fact, research into periventricular nodular heterotopia genetics has revealed that aberrant neuronal migration leads to clusters of neurons in the subependymal region. Consequently, these abnormal clusters often trigger genetic epilepsy. Although seizures can occur shortly after birth, they most frequently emerge during the second decade of life. Notably, generalized tonic-clonic seizures are the most common manifestation observed in clinical practice.
Historically, clinicians have identified the FLNA gene as the primary driver of this condition. This X-linked gene plays a critical role in actin-binding and cell motility. However, recent studies emphasize that PVNH is a highly genetically heterogeneous disease. Therefore, identifying additional risk genes is essential for better patient outcomes. Genes such as ARFGEF2, MAP1B, and NEDD4L have also been implicated in the pathogenesis of PVNH. Furthermore, these discoveries highlight that various molecular pathways can lead to similar pathological manifestations.
Human cerebral organoids and animal models provide significant insights into the pathogenesis of this disorder. These models allow researchers to observe how specific gene products affect brain development. In addition, advanced neuroimaging remains the gold standard for identifying subependymal nodules. Since many variants are understudied, an updated spectrum of risk genes is vital for precision medicine. Thus, ongoing research continues to expand our understanding of how these genetic changes lead to epilepsy and developmental anomalies.
The most common symptom is epilepsy, particularly generalized tonic-clonic seizures. Many patients remain asymptomatic until their teenage years, when seizures typically begin.
PVNH is often inherited in an X-linked dominant pattern associated with the FLNA gene. However, it can also follow autosomal recessive or de novo patterns depending on the specific gene variant involved.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional relationship. Refer to the latest local and national guidelines for clinical practice.
References
Song J et al. Gene variants in periventricular nodular heterotopia. Acta Epileptol. 2026 May 02. doi: undefined. PMID: 42067951.
Guerrini R, Parrini E. Neuronal migration disorders. Neurobiol Dis. 2023.
Parrini E et al. Genetic Heterogeneity of Periventricular Nodular Heterotopia. Front Cell Neurosci. 2022.

A review of genetic variants in periventricular nodular heterotopia (PVNH), focusing on FLNA and emerging risk genes associated with epilepsy....
last month

A study on hospitalists in central Michigan identifies key physician burnout factors, highlighting that married or partnered clinicians report significantly lower client-related and overall burnout. These findings suggest that while spousal support is protective, systemic workplace changes remain necessary.
Today

New research suggests that visceral adipose tissue inflammation, marked by adipocyte hypertrophy and crown-like structures, offers a deeper look into endometrial cancer risk than BMI alone. This metabolic dysfunction correlates with hepatic steatosis and systemic comorbidities in affected women.
Today

The prospective VAACS study reveals that hypertension significantly alters the predictors of postoperative hallucinations after cardiac surgery. While EuroSCORE II and valve surgery predict issues in hypertensive patients, anesthesia duration is the key factor for non-hypertensive cohorts.
Today

Research reveals how novel KIF22 variants disrupt mitosis in human chondrocytes, defining two mechanistic classes of dysregulation that lead to the rare skeletal disorder SEMDJL2.
Today

This research explores how 3D genome architecture and epigenetic regulation control lineage identity in advanced prostate cancer, offering new insights into treatment resistance and potential therapeutic targets for castration-resistant and neuroendocrine phenotypes.
Today